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Abstract
Background: The exact relationship between nucleosome positioning and methylation of CpG islands in human
pathogenesis is unknown.
Methodology/Principal Findings: In the present study, we characterized the nucleosome position within the p16 CpG
island and established a seeding methylation-specific PCR (sMSP) assay based on bisulfite modification to enrich the p16
alleles containing methylated-CpG at the methylation ‘‘seeding’’ sites within its intron-1 in gastric carcinogenesis. The sMSP-
positive rate in primary gastric carcinoma (GC) samples (36/40) was significantly higher than that observed in gastritis (19/
45) or normal samples (7/13) (P,0.01). Extensive clone sequencing of these sMSP products showed that the density of
methylated-CpGs in p16 CpG islands increased gradually along with the severity of pathological changes in gastric tissues. In
gastritis lesions the methylation was frequently observed in the region corresponding to the exon-1 coding-nucleosome
and the 59UTR-nucleosome; the methylation was further extended to the region corresponding to the promoter-
nucleosome in GC samples. Only few methylated-CpG sites were randomly detected within p16 CpG islands in normal
tissues. The significantly inversed relationship between the p16 exon-1 methylation and its transcription was observed in GC
samples. An exact p16 promoter-specific 83 bp-MSP assay confirms the result of sMSP (33/55 vs. 1/6, P,0.01). In addition,
p16 methylation in chronic gastritis lesions significantly correlated with H. pylori infection; however, such correlation was not
observed in GC specimens.
Conclusions/Significance: It was determined that de novo methylation was initiated in the coding region of p16 exon-1 in
gastritis, then progressed to its 59UTR, and ultimately to the proximal promoter in GCs. Nucleosomes may function as the
basic extension/progression unit of de novo methylation of p16 CpG islands in vivo.
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Introduction
Methylation of CpG islands around transcription start sites
(TSS) represses gene expression epigenetically and plays crucial
roles in cell differentiation, development, and pathogenesis. It has
previously been reported that nucleosome positioning may
influence DNA methylation patterns throughout the genome,
and DNA methyltransferases preferentially target nucleosome-
bound DNA in the Arabidopsis thaliana and human embryonic stem
cells [1]. However, the mechanistic details describing the role of
nucleosome positioning in relation to DNA methylation are still
unknown. Attempts to characterize exact aberrant methylation
and its extension patterns within CpG islands in human tissue
samples, especially in the early stage of carcinogenesis, have not
been successful for variety of reasons. Problems arise from the fact
that only a very small fraction of cells undergo de novo methylation
(extension) in cellular heterozygous tissues making detection
difficult, and the sensitivity limits of current approaches are
unable to determine the methylation and demethylation patterns
dynamically.
Tumor suppressor gene p16 (CDKN2A) is a cell cycle regulator
involved in inhibiting the G1RS phase transition [2]. Aberrant
methylation of CpG islands is the main mechanism for p16
inactivation in multiple human cancers [3–5]. p16 Methylation is
an early event in carcinogenesis and has been shown to
significantly increase the risk of malignant transformation of
epithelial dysplasia in the stomach, oral cavity, and other organs in
followup cohort studies [6–9]. In fact, it is undergone to develop
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precancerous lesions [10,11].
Although p16 methylation is one of the well-studied epigenetic
events [12–16], most of our knowledge on this event originated
from studies using in vitro cell culture systems, in which full
methylation of p16 CpG islands has been established. However,
full methylation is not often detectable in tissue samples, especially
in the early stages of carcinogenesis. Although methylation-specific
PCR (MSP) or MethyLight assays targeted to the p16 exon-1
region are the most widely used assays [11,17,18], the natural
methylation patterns of each CpG site within this CpG island in
human tissues with/without pathological changes have not been
comprehensively studied at a single molecule level.
It has been reported that p16 methylation is very stable in
cultured cancer cell lines based on its efficient recovery after the
removal of a DNA methylation inhibitor treatment [19]. In
contrast, most p16 methylation in gastritis lesions is unstable and
H. pylori-dependent as indicated by the 150 bp-MSP assay [20,21].
The mechanisms contributing to the difference in stability of p16
methylation between gastritis and cancer cells is unknown.
Characterization of the natural methylation pattern of p16 CpG
islands in human tissue samples of various pathological states may
elucidate the mechanisms accounting for the diverse stability of
p16 methylation and could potentially be used to develop a tumor-
specific methylation biomarker assay. In the present study, we
explored the relationship between the natural methylation
signatures of p16 CpG islands and nucleosome positioning in
human gastric carcinogenesis.
Materials and Methods
Tissue samples and H. pylori status
Surgical GC samples from 68 patients (49 males and 19 females,
35–81 years old), chronic gastritis biopsies from 45 patients (33
males and 12 females, 18–65 years old) and gastric mucosa
biopsies from 13 healthy male subjects (18–47 years old) were
obtained from the Peking University Cancer Hospital/Institute.
All these tissues were histologically verified. The Ethnics
Committee of the Peking University Cancer Hospital/Institute
approved the study. The written, informed consent was obtained
from all subjects. The H. pylori status was determined using a PCR
assay to amplify H. pylori-specific 23S rDNA as described [22].
Cell culture
Human cancer cell line MGC803 was cultured in RPMI 1640
medium with 10% FBS at 37uC and 5% CO2. AGS (ATCC#
CRL-1739) was cultured in F12 medium with 10% FBS.
MGC803 and AGS cell lines were kindly provided by Prof. Yang
Ke at the Cancer Institute [23]. We reported the p16 methylation
and expression data of these two cell lines previously [13].
DNA preparation, bisulfite treatment and clone
sequencing
Genomic DNA was extracted from tissue samples with phenol/
chloroform. The unmethylated cytosine of the genomic DNA was
converted to uracil through treatment with 5 mol/L sodium
bisulfite for 16 hrs at 50uC [24]. Bisulfite genomic sequencing was
used to analyze the methylation patterns of individual DNA
molecules. PCR products were amplified from the bisulfite-treated
DNA templates with primer sets complementary to the deami-
nated DNA as described below. The amplicons were cloned into
the pCR-blunt vector (Invitrogen, Carlsbad, CA), transformed into
E. coli, and sequenced using an ABI 3730 Analyzer. At least 20
clones were then randomly selected and sequenced for each
sample. To demonstrate the initiation and extension of de novo
methylation of p16 CpG islands, the methylation status of each
clone was analyzed as a categorical variable positive: methylation
level $5%, that is when the methylated CpG sites in a analyzed
fragment (including 48 tested CpG sites) in the p16 CpG island is
$3, it is defined as initially methylated molecules. Otherwise, we
designated it as methylation-negative.
Relative enrichment (chromatin accessibility) measured
by quantitative PCR
To determine the relationship between methylation and the
nucleosome occupancy in p16 CpG islands, a set of quantitative
PCR assays were performed in a similar manner to previously
published studies with minor modifications [25–28]. The mono-
nucleosomal DNA from p16-methylated AGS and p16-unmethy-
lated MGC803 cell lines was isolated using the EZ nucleosomal
DNA Prep Kit (Zymo Research, Orange, CA) according the
manufacturer’s instructions. Briefly, the procedure includes cell
nuclei isolation, intact nuclei micrococcal nuclease (MNase)
digestion, and mono-nucleosomal DNA purification. DNA
recovered from the MNase ‘Cut’ and ‘Uncut’ control samples
was used in quantitative PCR assays to measure the relative
enrichment of targeted regions using a series of primer pairs
(Fig. 1b and 1c; Table S1). For each primer set, the forward and
reverse primers were designed to cover within 147 bp of the
template sequence, which theoretically constitutes the core DNA
region of a nucleosome. Each PCR was performed in duplicate.
The following quantitative PCR conditions were used: 95uC for
15 min, and 45 cycles of 95uC for 10 s, 62uC for 20 s, and 72uC
for 20 s, followed by 72uC for 10 min. All PCR reactions were
performed using the power SYBR Green PCR Master Mix (P/N
4367659, Applied. Biosystems, Foster City, CA) on an ABI-7500
Real-Time PCR system (Applied Biosystems). Relative enrichment
was calculated according to the relative copy number (2
2DCt;
DCt=Ct
Uncut2Ct
Cut) for each primer set [24,26]. Thus, MNase-
hypersensitive fragments in nucleosome-free regions (with high
chromatin accessibility) such as linker DNA were depleted in the
MNase-treated samples and gave lower relative enrichment than
those with the MNase-hyposensitive ones (with low accessibility)
such as coral nucleosomal fragments.
PCR amplifications
CpG-free forward and reverse primers (59-gtagg tgggg aggag
tttag tt-39 and 59-ctacc taatt ccaat tcccc taca-39) were used to
amplify both the methylated and unmethylated p16 CpG islands
(588 bp). The same region was also amplified by sMSP (forward
primer, 59-gtagg tgggg aggag tttag tt-39; reverse primers, 59-ccaat
tcccc tacaa acttCG-39,5 9-ccaat tcccc tacaa acttc atcct ccaaa atCG-
39 and 59-ccaat tcccc tacaa acttc atcct ccaaa atcac cCG-39). The
forward primer and three reverse primers were used in the same
reaction. The touchdown PCR was initiated at an annealing
temperature of 62uC and decreased by 1uC per cycle for 10 cycles
followed by 30 additional cycles at an annealing temperature of
52uC. 83 bp-MSP (primers for the 83 bp amplicon of methylated-
p16,5 9-cgatt ttagg ggtgt tatat tcgtt aagtg ttc-39 and 59-aaaca aaaaa
acgcc gtaaa cgaat actcg-39; primers for the 88 bp amplicon of
unmethylated-p16,5 9-gtgat tttag gggtg ttata tttgt taagt gtttg-39 and
59-ttcca aacaa aaaaa cacca taaac aaata ctca-39). The following
PCR conditions were used: 95uC for 15 min, and 38 cycles of
95uC for 30 s, 59uC for 30 s, and 72uC for 30 s followed by 72uC
for 10 min. The 88 bp-MSP assay was used to detect unmethy-
lated p16 alleles in all tested tissue samples.
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To detect the relative p16 mRNA level in gastric biopsy, Power
SYBR Green PCR Master Mix (ABI) was used in the quantitative
RT-PCR as described previously [13].
Detection of p16 methylation with 392 bp DHPLC assay
The fully methylated-p16 alleles in gastric tissues was detected
using the 392 bp DHPLC assay and fluorescence detector as we
reported previously [29].
Results
Nucleosome positioning across p16 CpG island in human
gastric carcinoma (GC) cell lines
To validate prediction data on the p16 nucleosome occupancy
in the human genome (Figure 1A) [28], we characterized
nucleosome position within p16 CpG island in the p16-methylated
human GC cell line AGS and the p16-unmethylated cell line
MGC803 (detected by 392 bp DHPLC) using the mono-
nucleosomal DNA as the template. The chromatin accessibility
was measured by a set of quantitative PCR to verify the predicted
nucleosome positioning (Figure 1B). We found that amplicons of
primer-2/4/7/8/9 sets were highly resistant to MNase digestion in
the AGS cell line suggesting the presence of a nucleosome core in
these regions. In contrast, amplicons of primer-1/3/5/6 sets
showed MNase digestion hypersensitive suggesting the existence of
nucleosome-free region such as linker DNA (Figure 1C). These
patterns are consistent with the predicted nucleosome occupancy
well [15,30]. Interestingly, the nucleosome signal in the amplicons
of primer-2, -8, -9 in the p16-methylated AGS cells was
significantly stronger than that in the p16-umethylated MGC803
cells. In addition, the hypersensitive region of the primer set-5,
which centered in the vicinity of the TSS of p16, showed virtually
no signals after PCR and might indicate the preferred position of
the linker DNA in the p16-methylated AGS cells. On the contrary,
the hypersensitive region around the TSS was not detectable in the
p16-unmethylated MGC803 cells, which suggests the existence of
a transcription factor complex.
Nucleosomes correlated with extension pattern of de
novo methylation of p16 CpG islands in human gastric
carcinogenesis
To illustrate the progressive p16 methylation pattern during
tumorigenesis and its correlation with nucleosome, we first used
the CpG-free primer set to amplify both the methylated and
unmethylated 588 bp fragments ranged from the proximal
promoter nucleosome to the coding nucleosome around the p16
TSS after bisulfite treatment. Bisulfite-sequencing showed that the
Figure 1. Chromatin accessibility determined by quantitative PCR across the p16 promoter. (A) Genomic organization of the p16
promoter and exon-1 region; Predicted nucleosome occupancy in A375 cells are depicted as black peaks and the fragment without nucleosome
signal are depicted as inverse gray peaks [29]. The previously reported nucleosome position (three ovals) and location of the 150 bp-MSP amplicon
(black line) are also illustrated [15,17]. (B) Amplicons of the chromatin accessibility measured through a set of quantitative PCR assays were used to
quantify the mono-nucleosomal DNA partially digested using MNase (Horizontal lines). The detected nucleosomes are marked using gray ovals.
Positions of these CpG sites in the p16 genomic sequence corresponding to the fragment displayed in panel A are indicated by thin vertical lines, and
the transcription start site (TSS) is represented as a bent arrow. (C) The relative enrichment of various fragments within p16 CpG island in p16-
methylated AGS and p16-active MGC803 cells with and without digestion using 0.1 U MNase for 5 min. Relative enrichment was calculated and
normalized according to the relative copy number (2
2DCt; DCt=Ct
Uncut2Ct
Cut) for each primer set [24,26]. The average value and standard deviation
of four quantitative PCR reactions are displayed. We reported the p16 methylation and expression data of these two cells previously [13].
doi:10.1371/journal.pone.0035928.g001
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clones (containing more than three methylated CpG sites) in two
representative GC samples F0160 and F0500 containing methyl-
ated-p16, respectively (Figure 2A). Interestingly, the methylated
CpG sites in the coding nucleosome were observed among all
methylation-positive p16 clones. Unfortunately, the ratio of
methylation-positive clones was too low to get enough number
of methylation-positive clones using bisulfite-sequencing to make a
solid p16 methylation pattern in these samples because of the
existence of large proportion of background methylation-negative
p16 alleles.
To better clarify how aberrant methylation in p16 promoter is
initially established from only a small portion of cells undergoing de
novo methylation, we sought to develop a more robust assay
capable of enriching initially methylated p16 molecules in gastric
biopsy samples with high sensitivity. It is reported that three 39-
CpG sites in the p16 intron-1 are the methylation seeding sites in
mammary epithelial cell strain (Supplementary Figure S1A,
under-blue-lined sites) [14]. In addition, methylation at these
seeding sites is frequently observed in all fully methylated p16
clones and most partially methylated clones from the primary GC
tissues in our previously published study (Figure S1B, blue-dots)
[29]. This phenomenon was observed again in the unbiased PCR
sequencing in the present study (Figure 2A, blue-dots). Thus, we
designed a novel seeding methylation-specific PCR (sMSP) to
enrich p16 molecules (588 bp) containing at least one of the
seeding methylated-CpG sites (Figure 2B, green-bars). A CpG-free
forward primer and three reverse primers matched to one of three
seeding methylated-CpG sites were used in the sMSP assay. To
further support and confirm the methylation data obtained using
sMSP, we sequenced the sMSP products and compared the results
with those obtained from the unbiased 588 bp products. As shown
in Figure 2B, the positive rate of methylation-positive p16 clones
increased from 6% (3/49) to 70% (14/20) and 11% (7/62) to 50%
(10/20) for the sample F0160 and F0500, respectively (Figure 2B).
Most importantly, the p16 methylation pattern obtained using the
sMSP-sequencing was similar to that using the unbiased PCR-
sequencing. Thus, the sMSP assay was used to analyze dynamic
processes of initiation and extension of p16 methylation during
gastric carcinogenesis as described below.
Using the sMSP assay, we first analyzed the p16 methylation in
99 gastric tissue samples with various pathological changes. Results
showed that 98 of 99 samples were p16 methylation informative
and that the sMSP-positive rate in GC samples (36/40) was
significantly higher than that of normal gastric biopsies (7/13) or
that of chronic gastritis lesions (19/45) (90% vs. 54% or 42%,
P=0.005 or 0.000). Then, all these sMSP products were
extensively clone-sequenced (approximately 20 clones per sample).
Sequencing information was obtained from 31 GC, 14 gastritis,
and 6 normal samples (Figure 3). The average proportion of
methylation of individual CpG site within the tested p16 fragment
was calculated based on all informative clones for each sample and
displayed in the corresponding gray-graded pattern (from dark to
blank, 8 grades; Figure 3B). The noise-level of sporadic methylated
CpG sites was randomly observed among 45 analyzed CpG sites
(except three anchoring methylated CpG sites at the reverse
primers) in normal gastric tissues, gastritis lesions, and GCs. To
standardize the primary data on methylation prevalence in
different groups of gastric tissues, we defined a CpG site in a
sample is methylated, when methylation of the CpG site was
observed in one of all informative clones from the sample and used
it to calculate the methylation positive rate of each CpG site
among GC, gastritis, and normal samples (Figure 3C). The
methylation positive rate in the promoter region in GCs is higher
than in gastritis and normal samples (Fish exact test, GC [8/31]
versus gastritis/normal [1/20] for the site-5, P,0.02; GC [6/31]
versus gastritis/normal [0/20] for the site-1, P=0.07). When the
density of methylation was calculated in statistical analysis, the
proportion of methylated CpG at the site-12 and site-13 in GCs
was also significantly higher than in normal and gastritis samples
(Mann and Whitney test, P=0.043, two-sides). A gradual
extension trend of de novo methylation within the CpG islands
from the exon-1 coding-nucleosome to the proximal promoter
(PP)-nucleosome was also observed from gastritis lesions to GCs.
To analyze the relationship between p16-methylation and its
transcription in gastric tissues, we quantified the relative p16
mRNA level in these tissues. Methylation status of p16 CpG
islands in these samples was also detected using the 392 bp-
DHPLC assay that was established to detect methylation in 35
CpG sites, including three seeding methylation sites [29]. The
relative p16 mRNA level in 14 GCs with methylated-p16 was
significantly lower than that in 26 GCs without methylated-p16
[DCt (mean 6 SD), 12.7962.77 versus 8.5163.32, P,0.001;
higher DCt value means lower mRNA level]. The methylated-p16
was only detected in one of 29 gastritis/normal samples in which
p16 mRNA was not detected. The positive detection rate of p16
mRNA in GC samples without p16 methylation was significantly
higher than that in gastritis/normal samples without p16
methylation (26/26 versus 15/28, P,0.001). The average p16
mRNA level [DCt, 13.3763.28] in these 15 p16-expressed
gastritis/normal samples was also much lower than that in the
GC samples with or without p16 methylation.
p16 Full methylation extended to the proximal promoter
might be a tumor-specific event
To clarify if the exact p16 promoter methylation is tumor-
specific, we further analyzed the methylation-positive clones
(containing $3 methylated-CpG sites) obtained from gastric
tissues using sMSP-sequencing. Our study showed that the largest
number of methylated-CpG sites within a single clone was never
higher than 14 among 67 clones from 6 sMSP-sequenced normal
gastric samples, and the number of methylation sites was never
more than 28 among 217 clones from 14 gastritis samples. In
contrast, clones containing more than 29 methylated-CpGs were
found among 460 clones from 31 GCs (Figure 4A). The
proportion of clones with $6 methylated-CpG sites from GCs
(16.7%) was also significantly higher than that from gastritis (8.3%)
or normal biopsies (7.5%) (77/460 vs. 18/217 or 5/67, p=0.003
or 0.050) (Figure 4B). The methylated-CpG cluster in the PP-
nucleosomal region was observed only in GC samples. Moreover,
we found that most p16 molecules containing promoter CpG
methylation were fully methylated across the CpG island.
Therefore, we reasoned that the methylation within this region
might be a tumor-specific event.
To exclude if the sMSP assay itself might lead to the promoter-
specific bias, we developed an 83 bp-MSP assay capable of
detecting CpG methylation across the linker region between the
PP- and 59UTR-nucleosomes (Figure 4C). Results of the 83 bp-
MSP assay confirmed the validity of the sMSP analysis. The
methylated-p16 by 83 bp-MSP was detected in 33 of 55 sMSP-
positive samples, but only in 1 of 6 sMSP-negative samples
(P,0.04) (Figure S2). The average methylation frequency at all 45
tested CpGs in the 83 bp-MSP-positive samples (N=32) is higher
than that observed in the negative samples (N=19) (Figure 4C).
Then, we used the 83 bp-MSP assay to detect p16 methylation in
more GC samples and gastritis/normal biopsy samples, and found
that the methylated-p16 was detected in 60.3% (41/68) GCs,
Nucleosome & p16 Methylation in Carcinogenesis
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35928Figure 2. Results of bisulfite-sequencing of the 588 bp fragment of the p16 CpG islands. (A) Sequences of the methylation-positive and
negative clones from the 588 bp unbiased PCR products amplified using a CpG-free primer set and bisulfite-treated genomic DNA templates of two
representative gastric carcinoma tissues containing methylated p16 by the 115 bp MethyLight assay [11]; (B) Sequences of the methylation-positive
and negative clones from the 588 bp sMSP products. Purple bars, methylated CpG sites; Blue bars, seeding methylated CpG sites detected in the
unbiased PCR products; Green bars, seeding methylated CpG sites used to design the sMSP primers. Each row presents one clone; Clone markers of
methylation-positive p16 molecules (containing more than three methylated-CpG sites) are highlighted with blue color. The standard sequence of the
fully methylated p16 amplicon and the primer-matched regions in each assay are demonstrated on the top part.
doi:10.1371/journal.pone.0035928.g002
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(p=0.043).
p16 Methylation positively correlated with the existence
of H. pylori in normal/gastritis
H. pylori infection is the main cause of gastritis; p16 methylation
in this lesion is H. pylori density- dependent [21]. In the present
study, we directly detected H. pylori genomic DNA in these
analyzed gastric samples using a H. pylori-specific 23S rDNA PCR
assay (Figure 5A), and found 46 samples containing H. pylori DNA
among 64 sequenced samples (17 of 26 GCs and 13 of 20 gastritis/
normal). The sMSP-positive rate of p16 methylation in the H.
pylori-positive samples was much higher than H. pylori-negative
samples (30/34 vs. 16/30, P,0.001).
We further analyzed the relationship between the existence of
H. pylori-DNA and the methylation status of 45 CpG sites in p16
CpG island among the 46 sMSP-positive samples. As expected, we
found that the methylation density of CpG site-27/31/36/37/42/
43 within the sequenced p16 fragment in the H. pylori-positive
normal/gastritis samples (N=13) was statistically significantly
higher than that in the H. pylori-negative ones (N=7), especially
in the exon-1 coding-nucleosomal region (Wann Whitney test,
P#0.040; Table 1 and Figure 5B). Unexpectedly, we found that
such difference could not be observed in GC samples. In contrast,
the density of methylated-CpG sites in the H. pylori-negative GC
samples (N=9) was even higher than those observed in the H.
pylori-positive samples (N=17), especially across the PP- and
59UTR-nucleosomal regions (Figure 5C).
Discussion
Over the past decade, numerous evidences indicate that DNA
methylation, nucleosome positioning, and histone modification
form a complex regulatory network to modulate gene expression
and genome function epigenetically [31,32]. The interplay
between DNA methylation and nucleosome occupancy has been
addressed recently [1,25,26]. It is reasonable to speculate that the
nucleosome, which typically consists of a 147 bp DNA fragment
and an octamer of histones H2A, H2B, H3, and H4, may act as
the basic de novo methylation unit in the initiation and extension
stages of methylation [26]. It was determined that RASSF1A
hypermethylation spreads progressively from its exon-1 to the
promoter during breast tumorigenesis [33]. In the present study,
the natural dynamics of this interplay were analyzed in a number
of human gastric tissues in different stages of carcinogenesis. We
found that de novo methylated-CpGs within p16 CpG islands were
concentrated and extended in a nucleosome-specific pattern. This
pattern of de novo methylation (extension) of p16 CpG islands
observed in human gastric mucosa was related to the development
of gastric carcinomas. To the best of our knowledge, this is the first
report to address the gradual progression and accumulation of de
novo methylation of p16 CpG islands in vivo.
It is generally considered that the aberrant full methylation of
CpG islands of the tumor suppressor genes of cultured cell lines
and cancer cells has been established, and that fraction of cells that
undergo de novo methylation in cellular heterogeneous tissues is
limited. However, the exact status of these epigenetic events in
tissues in different pathological stages of carcinogenesis is not well
studied. The major obstacle in characterizing aberrant de novo
methylation patterns of CpG islands in vivo is the difficulty
associated with capturing DNA molecules in the initiation and
extension stages of methylation. As we display in Figure 2A, the
efficiency of the unbiased bisulfite-sequencing is very low. A
methylation enrichment technology should be used to determine
the initiation and extension pattern of p16 methylation. Although
5-methylcytosine antibody or methylated-DNA binding protein
immunoprecipitation (MeDP) is the regular approach for enrich-
ment of methylated-DNA, however, whether this approach is
suitable to enrich DNA fragments with methylation initiation in
small tissue samples, such as gastric mucosa biopsies, is unknown.
Thus, we have to establish other sensitive method to enrich the
methylation-positive p16 molecules. It has been reported that three
CpG sites in the p16 intron-1 may be the seeding methylation sites
for the initiation of p16 methylation [14]. Our present and
previously reported studies using bisulfite sequencing of 588 bp
and 392 bp unbiased PCR products show that these CpG sites are
indeed initial methylation sites, as we demonstrate in Figure 2A
(blue bars) and Supplementary Figure S1 (blue dots), because
methylation of the seeding sites can be observed not only in the
fully or extensively methylated clones, but also in most of these
clones containing a few methylated CpG sites. Therefore, based on
these observations, we developed a novel approach, sMSP, to
enrich the p16 molecules that are methylated at least at one of
three seeding methylation sites in tissue samples. In two
representative GC samples, we found the p16 methylation patterns
obtained using the unbiased bisulfite-sequencing and sMSP were
similar, but the efficiency of sMSP to capture the methylation-
positive molecules is about 5 times of the unbiased assay.
Extensive clone sequencing of the sMSP products demonstrated
clearly that in normal gastric tissue the majority of the samples did
not show CpG methylation or contained sporadically methylated-
CpG sites in the exon-1 coding-nucleosome region. In contrast,
the gastritis and GC samples showed various degrees of
methylation in the same region. Extensive methylation in both
the promoter and the exon-1 regions was observed in the majority
of the GC specimens. We propose that a methylation wave
progressively extends from the p16 exon-1 coding-nucleosome to
its promoter nucleosome in vivo. The overall p16 methylation
profiles constructed from a panel of clinical specimens may
approximate the natural extension pattern of de novo methylation of
p16 CpG islands in gastric carcinogenesis.
Other studies have revealed that the methylation process in the
CpG islands of genes in cultured cells contain ‘hot spots’ that are
considerably more prone to methylation [16]. Our in vivo study
identified similar ‘hot spots’ in similar locations observed in clinical
specimens. We also propose the possibility that the focal ‘hot spots’
and the wave-extension pattern could directly reflect the
nucleosome positioning. This compelling observation correlates
well with recent findings of increased methylation density within a
nucleosome of a susceptible CpG island [1]. The underlying
Figure 3. Relationship between nucleosome positioning and methylation of each CpG site within p16 CpG island in human gastric
mucosa samples (N=51). (A) The detected nucleosome occupancy within a p16 CpG island as displayed in Figure 1B; three seeding methylation
CpG sites at 46, 47, and 48 locations are marked with purple color; (B) A gray-graded representation of the average methylation density at individual
CpG sites within the p16 promoter and exon-1 region based on the results of all informative clones obtained from each sample using the sMSP-
sequencing assay; The methylation density of each CpG site in each tested sample was labeled, 0.1,0.7 mean 10%,70%; (C) The positive rate of
methylated-CpG at each CpG site in the sequenced gastric tissue samples with various pathological changes. *, The positive rate at the site-5 in GCs is
statistically significantly higher than in gastritis and normal samples (Fish exact test, P,0.02). #, The positive rate at the site-12 and 13 GCs is
significantly higher than in gastritis and normal when the proportion value of each sample was used in the Mann Whitney test (P=0.043, two-sides).
doi:10.1371/journal.pone.0035928.g003
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35928Figure 4. Comparison of methylation status of p16 CpG island in gastric carcinomas (GC), chronic gastritis, and normal gastric
mucosa using sMSP-sequencing. (A) Proportion of clone groups containing different number of methylated-CpG sites within the bisulfite-
sequenced clones; (B) The proportion of clones containing $6 methylated-CpGs in sMSP clones from GCs (16.7%) was significantly higher than that
from gastritis (8.3%) or normal biopsies (7.5%) (77/460 vs. 18/217 or 5/67, p=0.003 or 0.050). The fully methylated-CpG cluster in the proximal
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35928molecular mechanism could be linked to DNMT preferentially
targeted nucleosome-bound DNA [1,34]. Histone modifications,
such as H3K27 trimethylation, maybe necessary for establishment
of p16 methylation [35]. The dependency of de novo methylation of
CpG islands on the presence of nucleosomes should be studied
further.
It is suggested that p16 methylation precedes the formation of
pre-neoplastic lesions, which indicate that epigenetic events might
play a role in the induction of oncogenic pathways in early stages
of carcinogenesis [6,7]. In fact, p16 methylation has the potential
to be the risk prediction biomarker for cancers in the stomach and
other organs [8–10]. However, extensive aberrant p16 methylation
in the exon-1 region was also observed in gastric tissues with
chronic gastritis as determined using the classic 150 bp-MSP assay
[21]. Unlike the stable p16 methylation in cancer cells [19], p16
methylation in gastritis lesions is unstable and H. pylori-dependent
as indicated through the 150 bp-MSP assay [20,21]. Various CpG
islands, as well as different regions within the same CpG island,
show different degrees of susceptibility to methylation [36]. To
develop an assay capable of using p16 as a tumor biomarker, it
would be necessary to search for distinct methylation regions
within a p16 CpG island where methylation is stable and cancer-
promoter (PP)-nucleosomal region was observed only in GC samples. Most p16 molecules with promoter methylation are fully methylated. (C) The
average methylation frequency of each CpG site within the 45 tested CpGs in the 83 bp-MSP-positive samples (n=32) and the negative samples
(n=19). The G in the CpG site-10 is a G/A polymorphism.
doi:10.1371/journal.pone.0035928.g004
Figure 5. Correlation between H. pylori infection and the average proportion of methylated-CpG site at each CpG site within p16
CpG island. (A) Result of 289 bp PCR products of H. pylori-specific 23S rDNA from 14 representative gastric samples detected as previous report [22];
(B) The methylation proportion of each p16 CpG site in the H. pylori-positive normal/gastritis biopsies (N=13) and the H. pylori-negative samples
(N=7); The gray ovals represent the nucleosome position; (C) The methylation proportion of each p16 CpG site in the H. pylori-positive GC samples
(N=17) and the H. pylori-negative GC samples (N=9).
doi:10.1371/journal.pone.0035928.g005
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35928Table 1. Comparison of the proportion of methylation at individual CpG site in the p16 CpG islands in GCs and gastritis/normal
biopsies containing or not containing H. pylori (Hp)-specific DNA.
Normal and Gastritis (%) Gastric carcinomas (%)
Average Median (25th–75th) Average Median (25th–75th)
Hp (2)( N=7) Hp (+)( N=13) Hp (2)( N=7) Hp (+)( N=13) Hp (2)( N=9) Hp (+)( N=17) Hp (2)( N=9) Hp (+)( N=17)
CpG site-1 0 0 0 (0–0) 0 (0–0) 8.9 1.8 0 (0–0) 0 (0–5.0)
CpG site-2 1.2 0 0 (0–0) 0 (0–0) 9.1 1.4 0 (0–7.1) 0 (0–0)
CpG site-3 0 1.2 0 (0–0) 0 (0–0) 5.1 2.3 0 (0–0) 0 (0–0)
CpG site-4 0 0.8 0 (0–0) 0 (0–0) 8.3 1.6 0 (0–0) 0 (0–0)
CpG site-5 0 0.6 0 (0–0) 0 (0–0) 8.8 1.5 0 (0–9.1) 0 (0–0)
CpG site-6 0 1.1 0 (0–0) 0 (0–0) 8.1 0.9 0 (0–6.3) 0 (0–0)
CpG site-7 1.0 0.6 0 (0–0) 0 (0–0) 9.4 1.3 0 (0–5.0) 0 (0–0)
CpG site-8 0 1.6 0 (0–0) 0 (0–0) 4.6 1.5 0 (0–0) 0 (0–0)
CpG site-9 0 2.3 0 (0–0) 0 (0–0) 8.0 2.4 0 (0–0) 0 (0–0)
CpG site-10 0 0.5 0 (0–0) 0 (0–0) 4.0 1.5 0 (0–0) 0 (0–0)
CpG site-11 0 0.9 0 (0–0) 0 (0–0) 8.5 1.0 0 (0–5.0) 0 (0–0)
CpG site-12 0 0.8 0 (0–0) 0 (0–0) 8.0 3.5 0 (0–5.0) 0 (0–0)
CpG site-13 0 1.4 0 (0–0) 0 (0–0) 8.3 3.5 0 (0–5.0) 0 (0–5.3)
CpG site-14 2.2 1.2 0 (0–0) 0 (0–0) 6.6 2.9 0 (0–0) 0 (0–6.7)
CpG site-15 3.2 0.3 0 (0–5.0) 0 (0–0) 6.9 2.5 0 (0–0) 0 (0–0)
CpG site-16 1.2 1.3 0 (0–0) 0 (0–0) 7.5 2.1 0 (0–5.0) 0 (0–0)
CpG site-17 1.8 5.0 0 (0–0) 0 (0–7.7) 11.4 3.9 0 (0–10.8) 0 (0–7.1)
CpG site-18 3.2 2.7 0 (0–5.0) 0 (0–6.7) 6.5 2.1 0 (0–5.0) 0 (0–0)
CpG site-19 3.2 3.6 0 (0–5.0) 0 (0–7.1) 10.2 3.2 0 (0–5.0) 0 (0–5.3)
CpG site-20 1.8 3.8 0 (0–0) 0 (0–7.7) 10.2 3.0 0 (0–5.0) 0 (0–0)
CpG site-21 3.8 2.7 0 (0–6.3) 0 (0–6.7) 11.7 2.6 2.7 (0–5.9) 0 (0–0)
CpG site-22 1.8 2.8 0 (0–0) 0 (0–6.7) 10.2 2.1 0 (0–5.0) 0 (0–0)
CpG site-23 1.8 7.2 0 (0–0) 7.1 (0–13.0) 11.1 4.0 0 (0–10.0) 0 (0–7.1)
CpG site-24 1.8 3.4 0 (0–0) 0 (0–7.1) 10.8 6.5 0 (0–10.0) 0 (0–5.9)
CpG site-25 1.8 5.9 0 (0–0) 0 (0–8.7) 11.4 5.4 0 (0–15.0) 0 (0–5.3)
CpG site-26 1.3 4.0 0 (0–0) 0 (0–7.1) 12.6 3.8 0 (0–7.1) 0 (0–5.3)
CpG site-27 0 6.0 0 (0–0) 5.9 (0–7.1)
a 9.4 2.6 0 (0–5.0) 0 (0–0)
CpG site-28 0.9 4.9 0 (0–0) 5.9 (0–7.1) 9.4 3.4 0 (0–5.0) 0 (0–6.3)
CpG site-29 0 3.9 0 (0–0) 0 (0–6.7) 11.0 2.5 0 (0–10.0) 0 (0–0)
CpG site-30 2.9 7.0 0 (0–3.1) 7.1 (0–11.8) 11.0 3.5 0 (0–15.0) 0 (0–6.7)
CpG site-31 0 3.9 0 (0–0) 0 (0–7.1)
b 10.7 2.9 0 (0–10.0) 0 (0–0)
CpG site-32 1.0 3.6 0 (0–0) 0 (0–6.7) 10.8 2.9 0 (0–15.0) 0 (0–0)
CpG site-33 0 5.9 0 (0–0) 4.3 (0–7.1) 12.1 3.1 0 (0–10.0) 0 (0–0)
CpG site-34 1.1 5.6 0 (0–0) 0 (0–6.7) 12.6 4.4 0 (0–10.0) 0 (0–0)
CpG site-35 1.2 3.6 0 (0–0) 0 (0–6.7) 13.4 3.7 0 (0–15.0) 0 (0–0)
CpG site-36 0 4.6 0 (0–0) 0.5 (0–7.7)
c 11.1 2.8 0 (0–15.0) 0 (0–0)
CpG site-37 0 6.0 0 (0–0) 7.1 (0–10.0)
d 11.1 5.6 5.0 (0–10.0) 0 (0–11.1)
CpG site-38 1.1 7.9 0 (0–0) 8.3 (0–11.8) 12.0 5.3 0 (0–16.2) 0 (0–11.1)
CpG site-39 2.3 5.5 0 (0–3.8) 0 (0–8.7) 10.8 6.0 0 (0–15.0) 0 (0–12.5)
CpG site-40 17.3 13.9 0 (0–10.4) 16.7 (6.7–21.4) 12.9 7.5 8.1 (0–30.0) 0 (0–11.1)
CpG site-41 18.4 14.1 7.7 (0–10.4) 13.3 (7.1–21.7) 14.8 8.0 8.1 (0–30.0) 0 (0–12.5)
CpG site-42 0.9 14.1 0 (0–0) 15.4 (13.3–17.4)
e 13.0 6.6 0 (0–30.0) 0 (0–12.5)
CpG site-43 2.1 11.9 0 (0–3.1) 13.0 (0–20.0)
f 12.0 6.1 2.7 (0–20.0) 0 (0–6.7)
CpG site-44 1.2 7.2 0 (0–0) 6.7 (0–10.4) 11.5 3.6 2.7 (0–15.0) 0 (0–0)
CpG site-45 3.5 11.9 0 (0–3.8) 13.3 (0–23.1) 11.0 7.8 5.4 (0–15.0) 0 (0–12.5)
a, b, c, d, e, fWann Whitney test, P=0.012, 0.040, 0.023, 0.010, 0.018, 0.003, 0.034.
doi:10.1371/journal.pone.0035928.t001
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proximal promoter nucleosome was only observed in GC samples
making this location a possible candidate for further development
of a tumor biomarker, and that nearly all of the p16 molecules with
promoter methylation were found to be fully methylated in GC
samples. These phenomenon suggest that fully methylated-p16
molecules (from the exon-1 to the promoter) maybe not only more
stable than partially methylated ones, but also tumor-specific. This
might account for the wide range of stability observed in various
methylated-p16 alleles from gastric tissues with different lesions.
The inversed relationship between p16 methylation and its
transcription repression was firmly established in cultured cell lines
[3,5,13]. Because most GC samples were sMSP-positive (36/40),
we had to use other assay to detect p16 methylation in GC samples
to analyze the methylation-repression relationship in GC samples.
The 392 bp DHPLC assay was established to detection methyl-
ation status of 35 CpG sites in the p16 exon-1, including three
seeding methylation CpG sites, as demonstrated on the supple-
mentary Figure S1B [13]. Thus we used the 392 bp-DHPLC assay
was selected to detect p16 methylation in the present study. The
significantly inversed relationship was observed between GC
samples with and without p16 methylation. In addition, p16 is one
of weakly transcribed tumor suppressor genes in normal tissues
including the stomach. Both upregulation of p16 in some cell
population and methylation-silence in other cell population can
often be observed in cervical cancers and precancerous tissues
[10]. In this study, we also observed both higher p16 mRNA level
and higher sMSP-positive rate in GC samples than in gastritis/
normal samples.
It is well recognized that H. pylori infection can induce gastritis,
gastric ulcers, and gastric MALT lymphoma. Although H. pylori
infection increases GC risk, the causal relationship between GC
and H. pylori infection has not yet been established. We previously
evaluated the density of H. pylori-like microorganisms in gastric
mucosa containing gastritis or dysplasia lesions under microscope
and found that the density positively correlated with the
prevalence of p16 methylation [21]. In the present study, we
directly detected the exact existence of H. pylori-specific 23S rDNA
in the analyzed DNA samples and found that the methylation at
the p16 exon-1 coding region did positively correlate with H. pylori
infection in normal gastric biopsies and gastritis lesions. Surpris-
ingly, such correlation could not be observed in GC specimens. In
contrast, an inversed relationship was observed between H. pylori
infection and methylation at all 45 tested CpG sites in GCs. This
result implies that other causal factors may be the main
contributors to the abnormal p16 methylation seen in GC samples.
It has been reported that polycyclic aromatic hydrocarbons (PAH)
exposure may induce CpG site-specific methylation in the p16
exon-1 region in peripheral blood lymphocytes from PAH exposed
workers [37]. We have reported that p16 methylation is a frequent
epigenetic event observed when gastric carcinogenesis is induced
in Wistar rats by the N-nitroso compound MNNG [7]. Similar
carcinogenic N-nitroso compounds are known to be synthesized
within the human stomach and have been reported to increase the
risk of GC [38,39]. Whether exposure of gastric chemical
carcinogens induces the full methylation of p16 in GC should be
studied further.
In conclusion, we demonstrate that p16 methylation evolves and
progresses throughout the promoter in a stepwise ‘‘normal-
RgastritisRcarcinoma’’ cascade, in which the methylation
signature is directly connected to the position of nucleosome.
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